ScreenPoint Medical is a brand that is devoted to improving breast cancer survival rates by detecting cancers at an earlier stage, allowing for more effective and less invasive treatment options. With a focus on patient outcomes, they work closely with breast clinicians to continually enhance their clinically proven deep learning algorithms in Transpara®. With over 40 years of experience in the development of deep learning Artificial Intelligence (AI) for mammography and breast imaging, ScreenPoint Medical is at the forefront of technological advancements in the field.

Founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, two renowned experts in quantitative breast image analysis and computer-aided detection, they have made significant contributions to leading breast imaging products. Their flagship product, Transpara, has been featured in multiple peer-reviewed publications that highlight its ability to enable significant clinical improvements in the timely diagnosis of breast cancer. Led by a team of esteemed board members and advisors, ScreenPoint Medical is dedicated to achieving higher breast cancer survival rates while minimizing patient distress and unnecessary treatments